Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

39.24 -0.93 (-2.30%)
Streaming Delayed Price Updated: 12:19 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corp. (NASDAQ: LQDA) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Announces Updates to Operations Leadership
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Announces $100 Million in New Financings
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
News headline image
MarketBeat Week in Review: 12/25 - 12/29
The Santa Claus rally took the S&P 500 up about 0.75%, but recession concerns linger as the full impact of the Fed's rate hikes hasn't hit the economy. 
Via MarketBeat
Topics Economy Stocks
News headline image
Liquidia: Court victory the awakening of an industry giant?
Liquidia's stock surged after an enormous court win against United Therapeutics, accompanied by analyst upgrades and insider buying. 
Via MarketBeat
Topics Intellectual Property
News headline image
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Announces Pricing of Public Offering of Common Stock
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
From Liquidia Corporation
Via GlobeNewswire
News headline image
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
News headline image
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
From Liquidia Corporation
Via GlobeNewswire
News headline image
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
From Liquidia Corporation
Via GlobeNewswire
News headline image
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023
From Liquidia Corporation
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.